Apogee Therapeutics, Inc. (APGE) — SEC Filings
Apogee Therapeutics, Inc. (APGE) — 46 SEC filings. Latest: 8-K (May 11, 2026). Includes 21 8-K, 6 SC 13G/A, 5 10-Q.
View Apogee Therapeutics, Inc. on SEC EDGAR
Overview
Apogee Therapeutics, Inc. (APGE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: Apogee Therapeutics, Inc. filed an 8-K on March 25, 2026, to report an "Entry into a Material Definitive Agreement" under Item 1.01, with the period of report being March 24, 2026. This filing indicates that Apogee has entered into a significant new agreement, which could impact its future operation
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Apogee Therapeutics, Inc. is neutral.
Filing Type Overview
Apogee Therapeutics, Inc. (APGE) has filed 2 4, 21 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 5 SC 13G, 1 DEFA14A, 2 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of APGE's 30 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$186.456M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $107.914M |
| Operating Margin | N/A |
| Total Assets | $626.159M |
| Total Debt | N/A |
Key Executives
- Jane Pritchett Henderson
- Carl Dambkowski, MD
- Peter Harwin
- Tomas Kiselak
- Erin O'Connor
- Abigail P. Johnson
Industry Context
Apogee Therapeutics operates in the highly competitive biotechnology sector, focusing on the development of novel biologics for inflammatory and immunology markets. This space is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key therapeutic areas like atopic dermatitis and asthma are crowded with both established pharmaceutical giants and emerging biotech firms, demanding continuous innovation and efficient capital deployment.
Top Tags
sec-filing (7) · financials (7) · 8-k (5) · operations (4) · biotech (4) · Biotechnology (3) · 10-Q (3) · disclosure (3) · R&D Spending (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $186.456M | Increased 62.2% from $114.928M in 2024 for the nine months ended September 30. |
| Research and Development Expenses | $156.268M | Increased 45.2% from $107.636M in 2024 for the nine months ended September 30. |
| Cash and Cash Equivalents | $107.914M | Decreased from $141.789M at December 31, 2024, indicating significant cash burn. |
| General and Administrative Expenses | $51.271M | Increased 53.7% from $33.353M in 2024 for the nine months ended September 30. |
| ATM Equity Offering Proceeds | $19.382M | Net proceeds from common stock issuance under the at-the-market program. |
| Net Loss (Q2 2025) | $55.2M | Increased from $35.1M in Q2 2024, reflecting higher R&D spend. |
| Net Loss (YTD Q2 2025) | $105.3M | Increased from $65.2M in YTD Q2 2024, driven by pipeline advancement. |
| R&D Expense (Q2 2025) | $47.8M | Up from $29.8M in Q2 2024, indicating significant investment in drug development. |
| R&D Expense (YTD Q2 2025) | $90.5M | Increased from $55.0M in YTD Q2 2024, showing accelerated clinical programs. |
| Cash & Equivalents (June 30, 2025) | $500.0M | Provides substantial runway for operations despite increasing burn rate. |
| Revenue (Q2 2025) | 0 | Consistent with a clinical-stage company, no commercial products yet. |
| Reporting Period End Date | 20250331 | Indicates the end of the financial quarter being reported. |
| Filing Date | 20250512 | Date the 10-Q was officially submitted to the SEC. |
| Fiscal Year End | 2023 | The primary year for compensation data reported in the filing. |
| Previous Year End Date | 2023-12-31 | Provides a comparative point for financial analysis. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant ownership stake in Apogee Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The continued institutional backing from FMR LLC could positively influence investor confidence in Apogee Therapeutics.","entity":"Apogee Therapeutics, Inc.","targetDate":"2024-08-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Apogee Therapeutics, Inc. (APGE)?
Apogee Therapeutics, Inc. has 46 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of APGE filings?
Across 46 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Apogee Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Apogee Therapeutics, Inc. (APGE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Apogee Therapeutics, Inc.?
Key financial highlights from Apogee Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for APGE?
The investment thesis for APGE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Apogee Therapeutics, Inc.?
Key executives identified across Apogee Therapeutics, Inc.'s filings include Jane Pritchett Henderson, Carl Dambkowski, MD, Peter Harwin, Tomas Kiselak, Erin O'Connor and 1 others.
What are the main risk factors for Apogee Therapeutics, Inc. stock?
Of APGE's 30 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Apogee Therapeutics, Inc.?
Recent forward-looking statements from Apogee Therapeutics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Apogee Therapeutics for the foreseeable future.","entit and 1 other predictions.